Virax Biolabs Group Ltd
VRAX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0001885827
No open-market purchases or sales by Virax Biolabs Group Ltd insiders were filed in the last 90 days; 2 institutions reported holding it in 13F filings for Q2 2026, worth $77.6K in total; no superinvestor holds it.
13F holders, Q1 2025
Institutional positions in Virax Biolabs Group Ltd as of Mar 31, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 4
- −3 vs. Q4 2024
- Shares held
- 63.1K
- +91 (+0.1%) vs. Q4 2024
- Total value
- $71.5K
- −$69.8K (−49.4%) vs. Q4 2024
- New holders
- 3
- 0 more added
- Sold out
- 6
- 1 more reduced
Compare with Q4 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting VRAX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 2 | $77.6K |
| Q1 2026 | 4 | $202.2K |
| Q4 2025 | 6 | $12.1K |
| Q3 2025 | 5 | $57.1K |
| Q2 2025 | 2 | $28.6K |
| Q1 2025 | 4 | $71.5K |
| Q4 2024 | 7 | $141.4K |
| Q3 2024 | 5 | $423.6K |
| Q2 2024 | 7 | $81.8K |
| Q1 2024 | 3 | $12.5K |
| Q4 2023 | 4 | $195.4K |
| Q3 2023 | 4 | $10.9K |
| Q2 2023 | 4 | $22.8K |
| Q1 2023 | 5 | $1.14M |
| Q4 2022 | 8 | $990.4K |
| Q3 2022 | 6 | $183.0K |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2025
Shares, value and share of portfolio for each institution holding Virax Biolabs Group Ltd; share changes are against Q4 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| UBS Group AG | 22,425 | $25.6K | 0.00% | −15,490−40.9% | Reduced |
| Two Sigma Securities, LLC | 13,627 | $15.5K | 0.00% | +13,627 | New |
| Citadel Advisors LLC | 13,539 | $15.4K | 0.00% | +13,539 | New |
| HRT Financial LP | 13,507 | $15.0K | 0.00% | +13,507 | New |
| XTX Topco Ltd | 0 | $0 | 0.00% | −11,863−100.0% | Sold out |
| Royal Bank of Canada | 0 | $0 | 0.00% | −10,400−100.0% | Sold out |
| R Squared Ltd | 0 | $0 | 0.00% | −2,700−100.0% | Sold out |
| Morgan Stanley | 0 | $0 | 0.00% | −100−100.0% | Sold out |
| Northwestern Mutual Wealth Management Co | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Tower Research Capital LLC (TRC) | 0 | $0 | 0.00% | −9−100.0% | Sold out |